Cello Health PLC (LON:CLL) insider Christopher Jones bought 22,726 shares of the business’s stock in a transaction that occurred on Tuesday, October 9th. The shares were bought at an average cost of GBX 132 ($1.72) per share, with a total value of £29,998.32 ($39,198.12).
CLL opened at GBX 127 ($1.66) on Friday. Cello Health PLC has a fifty-two week low of GBX 115 ($1.50) and a fifty-two week high of GBX 140 ($1.83).
The business also recently announced a dividend, which will be paid on Friday, November 2nd. Investors of record on Thursday, October 4th will be paid a dividend of GBX 1.10 ($0.01) per share. The ex-dividend date is Thursday, October 4th. This represents a yield of 0.82%.
Separately, FinnCap reaffirmed a “corporate” rating on shares of Cello Health in a research note on Wednesday, September 19th.
About Cello Health
Cello Health plc, together with its subsidiaries, provides marketing services in the United Kingdom, Rest of Europe, the United States, and internationally. It operates in two segments, Cello Health and Cello Signal. The Cello Health segment offers market research, consulting, and communications services principally to the pharmaceutical and healthcare clients.
Recommended Story: Balance Sheet
Receive News & Ratings for Cello Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cello Health and related companies with MarketBeat.com's FREE daily email newsletter.